Clinical Trial Update: Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of bortezomib and rituximab for post-transplant lymphoproliferative disorders was terminated, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Lymphoproliferative Disorder | Phase 2 | Status: TERMINATED | Results posted: 2017-04-05